BioSpace News Archive

Pasithea Therapeutics Corp. announced that Camac Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney, and Avi Geller satisfied the necessary requirements to call a Special Meeting of Stockholders.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 50,000 shares of Akebia’s common stock on September 30, 2022, as inducements material to each such employee entering into employment with Akebia.

First of three approved U.S. oncology biosimilars Amneal expects to launch Amneal Pharmaceuticals, Inc. announced the commercial launch of ALYMSYS®, a biosimilar referencing Avastin®.

Connect Biopharma Holdings Limited announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis.

Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 4 new employees inducement stock options to purchase an aggregate of 20,800 common shares, at a per share exercise price of $7.52, the closing price of Aurinia’s common stock on September 30, 2022, and an aggregate of 12,500 inducement restricted stock units.

TCR2 Therapeutics Inc., a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 19,400 shares of TCR2’s common stock to 1 new non-executive employees.

Adamis Pharmaceuticals Corporation announced that following the recently announced halting of the Company’s Phase 2/3 clinical trial examining the effects of Tempol in high risk subjects with early COVID-19 infection, it has initiated a process to explore a range of strategic and financing alternatives focused on maximizing stockholder value.

ImmunoGen, Inc. announced that on September 30, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 1,067,850 shares of its common stock to thirty-seven new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.

Johnson & Johnson will participate in the Credit Suisse 31st Annual Global Healthcare Conference on Thursday, November 10th, 2022 at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 12:50 p.m.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 242,000 shares of its common stock to seven employees outside Cullinan Oncology, Inc.’s 2021 Stock Option and Incentive Plan.